期刊文献+

单唾液酸四己糖神经节苷脂钠联合依帕司他治疗糖尿病周围神经病变疗效观察 被引量:14

下载PDF
导出
摘要 目的探讨单唾液酸四己糖神经节苷脂钠(GM-1)联合依帕司他治疗糖尿病周围神经病变(DPN)的临床疗效。方法将60例2型糖尿病合并周围神经病变患者随机分为治疗组和对照组各30例,对照组采用依帕司他治疗,治疗组采用依帕司他联合GM-1治疗,疗程均为4周。两组治疗前后行神经电生理检查,检测双侧上、下肢的感觉神经传导速度(SNCV)、运动神经传导速度(MNCV)及胫神经的H反射潜伏期,并观察临床疗效。结果治疗组总有效率(76.7%)高于对照组(60.0%),SNCV、MNCV快于对照组(P均<0.05);两组胫神经的H反射潜伏期比较无统计学差异(P>0.05)。结论与单用依帕司他治疗比较,GM-1联合依帕司他治疗DPN临床疗效好、神经传导速度改善明显。
出处 《山东医药》 CAS 2013年第25期54-55,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

  • 1范冠杰(指导),孙素红,张宏生.糖尿病周围神经病变的临床疗效评定标准归类及分析[J].广西中医学院学报,2007,10(3):88-90. 被引量:26
  • 2Head KA. Peripheral neuropathy: pathogenic mechanism and alter- native therapies [J]. Altern Med Rev, 2006,11 (4) :294-329.
  • 3Hotta N, Kawamori R, Fukuda M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other mierovaseular complications: multivariate epide- miological analysis based on patient background factors and severity of diabetic neuropathy[J]. Diabet Med, 2012,29(12) :1529-1533.
  • 4Morano S, Tiberti C, Cristina G, et al. Autoimmune markers and neurological complications in non-insulin-dependent diabetes melli- tus[J]. Hum Immunol. 1999, 60(9) :848-854.
  • 5李妮,周微雅,陈晖,钟华,张丽香.糖尿病神经病变血清抗神经节苷脂抗体的观察[J].广西医学,2004,26(12):1760-1762. 被引量:1
  • 6Boslem E, Meikle PJ, Biden TJ. Roles of ceramide and sphingolip- ids in pancreatic β-cell function and dysfunction[ J]. Islets, 2012, 4(3) :177-187.
  • 7曹平,刘雪辉,胡泉.依帕司他治疗糖尿病周围神经病变60例临床分析[J].中国老年学杂志,2011,31(18):3595-3596. 被引量:16

二级参考文献25

  • 1罗邦尧,赵咏桔,陈宇红,冯凭,高志红,张本恕,王家弛,郑少雄.依帕司他治疗糖尿病周围神经病变有效性和安全性的临床研究[J].继续医学教育,2005,19(1):58-60. 被引量:22
  • 2Hotta N. New approaches for treatment in diabetes : aldose reductase inhibitors [J]. Biomed Phamacother, 1995 ;49 (5) :232-43.
  • 3Harris MI, Couric CC, Reiber G, et al. Diabetes in America[ M]. 2nd ed. Washington, DC, U. S. Govt : Printing Office, 1995:95-1468.
  • 4The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy[J]. Ann Intern Med, 1995 ; 122 ( 8 ) :561-8.
  • 5Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy[J]. Diabetes care,2001 ;24 ( 10 ) : 1776-82.
  • 6Lee AY, Chung SS : Contributions of polyol pathway to oxidative stress in diabetic cataract[J]. FASEB J,1999;13( 1 ) :23-30.
  • 7Feldman EL , Stevens MJ, Thomas PK, et al. A practical Twe-Step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy[J] . Diabetes Care , 1994,17(11) :10 281~10 289.
  • 8Schwerer B , Lassmann H , Kitz K, et al . Ganglioside GM1 , a molecular traget for immunological and toxic attackes : similarity of neuropathological lesions induced by ganglioside- antiserum and cholera toxin[J]. Acta Neuropathol(berl),1986,72(1):55.
  • 9Kroemer G, Wick G.The role of interleukin-2 in autoimmunity[J].Immunol Today, 1989, 10(7): 246.
  • 10钱荣立.中国糖尿病防治指南[M].北京:北京大学医学出版社,2004:18-11,72.

共引文献40

同被引文献134

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部